It Seems CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) Will Go Up. Just Reported Less Shorted Shares

September 12, 2017 - By Vivian Currie

The stock of CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) registered a decrease of 18.52% in short interest. CTTC’s total short interest was 4,400 shares in September as published by FINRA. Its down 18.52% from 5,400 shares, reported previously. With 52,100 shares average volume, it will take short sellers 0 days to cover their CTTC’s short positions.

About 300 shares traded. Calmare Therapeutics Inc (OTCMKTS:CTTC) has 0.00% since September 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Calmare Therapeutics Incorporated is a medical device company. The company has market cap of $3.06 million. The Firm is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. It currently has negative earnings. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain.

More notable recent Calmare Therapeutics Inc (OTCMKTS:CTTC) news were published by: Seekingalpha.com which released: “Why Competititve Technologies Could Be Ridiculously Undervalued” on May 15, 2011, also Seekingalpha.com with their article: “Turnaround Strategy Being Implemented At Competitive Technologies” published on March 13, 2014, Businesswire.com published: “Calmare Therapeutics Incorporated Uplists” on May 23, 2016. More interesting news about Calmare Therapeutics Inc (OTCMKTS:CTTC) were released by: Finance.Yahoo.com and their article: “Calmare Therapeutics Medical Device and Peripherals Now Listed for Sale on GSA …” published on January 26, 2017 as well as Businesswire.com‘s news article titled: “Calmare Therapeutics Incorporated Appoints Christine Chansky, MD, JD, FCLM …” with publication date: February 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.